"Govt initiatives and private sector investments are boosting adoption of NGS technologies for various applications"

Illumina, a global leader in DNA sequencing and array-based technologies, recently launched the MiSeq i100 and MiSeq i100 Plus Systems.

- Varun Raj, Regional Marketing Manager - India and Southeast Asia, Illumina

These two powerful, compact benchtop sequencers incorporate more than 140 invention disclosures and 60 patent families. The Illumina MiSeq i100 Series is its first customer-installable instrument since the iSeq. The MiSeq i100 Series builds on the legacy of the original benchtop MiSeq System, which Illumina customers have used since 2011 to power a host of genomic discoveries. Completely redesigned and incorporating the groundbreaking technology and chemistry of the NovaSeq X Series, the MiSeq i100 will help fuel the next generation of genomics growth and discovery. In an interaction with BioSpectrum Varun Raj, Regional Marketing Manager - India and Southeast Asia, Illumina shared more details about the series and how the company will take this product to end users and more. Edited excerpts;

Which are the industry challenges that the MiSeq i100 will solve for the benefit of the scientific community?

Our customers in the scientific community told us they need a faster, smaller, and easy-to-use instrument, and that’s what we're delivering with the MiSeq i100.

Whether an established next-generation sequencing lab or a lab looking to start sequencing for the first time, our latest benchtop instrument adds the ‘plug-and-play’ flexibility that today's labs are seeking.

MiSeq i100 is empowering customers to unlock powerful insights through an affordable, comprehensive solution that is simple to understand and use, even for those with limited NGS expertise. Room-temperature storage and shipping enable labs to sequence on demand, with no delays for thaw time and same-day sample-to-analysis.